Retracted: Inositol polyphosphate‐4‐phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3‐kinase/protein kinase B pathway

• DOI: 10.1002/jcb.27311
• Publication Date: 2018-08-22T16:10:15Z
• Authors: Dong Li; Jingyan Yang; Huanzhi Ma; Chengliang Sun; Rongjie Feng
• Keywords: Phosphoinositide 3-kinase; Polyphosphate

Abstract Osteosarcoma (OS) is an aggressive malignant tumor of bone, which often occurs in children and adolescents. Currently, the effective method for treatment OS still limited. The study aimed to investigate synergistic antitumor effect inositol polyphosphate‐4‐phosphatase, type‐II (INPP4B) rucaparib on cells. expression levels INPP4B tissues cell lines were examined by quantitative real‐time polymerase chain reaction Western blot analysis. SaOS2 U2OS cells then transfected with overexpression vector or treated different concentrations rucaparib, viability, cycle, apoptosis determined 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide flow cytometry. assay uncovered combined effects phosphoinositide 3‐kinase/protein kinase B (PI3K/AKT) signal pathway. Further, formation was vivo. Results showed that low expressed lines. significantly decreased viability induced Additionally, remarkably reduced a dose‐dependent time‐dependent manner. Meanwhile, suppressed cycle progression S phase promoted combination declined Myc, cyclin E1 D1 expressions, enhanced Bad, Bax, cleaved‐caspase‐3 blocked PI3K/AKT pathway Finally, inhibited demonstrated exhibited regulating